Literature DB >> 3260766

In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

N X Chin1, H C Neu.   

Abstract

The in vitro activity of R-3746, an iminomethoxy aminothiazolyl cephalosporin with a CH2OCH3 moiety at position 3, was compared with those of other antibiotics. R-3746 inhibited the majority of hemolytic streptococci (groups A, B, C, F, and G) and Streptococcus pneumoniae at less than 0.06 micrograms/ml, which was comparable to the activity of amoxicillin, 2- to 8-fold more active than cefixime, and 16- to 64-fold more active than cefaclor and cephalexin. Ninety percent of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae were inhibited at a concentration 0.25 micrograms/ml, but it was less active against Branhamella spp. It did not inhibit (MIC, greater than 16 micrograms/ml) enterococci, viridans group streptococci, or methicillin-resistant staphylococci. The MICs of R-3746 for 90% of strains tested for Escherichia coli; Klebsiella pneumoniae; Citrobacter diversus; Proteus mirabilis; and Salmonella, Shigella, and Yersinia spp. were less than or equal to 1 micrograms/ml. It was two- to eightfold less active than cefixime but was markedly superior to cefaclor, cephalexin, amoxicillin-clavulanate, and trimethoprimsulfamethoxazole. R-3746 inhibited 50% of Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Morganella spp., Providencia spp., Proteus vulgaris, and Serratia marcescens at less than or equal to 8 micrograms/ml. Pseudomonas spp. were resistant. Fifty percent of Clostridium spp. were inhibited by 0.5 micrograms/ml, but MICs for Bacteroides spp. were greater than 128 micrograms/ml. R-3746 was not appreciably hydrolyzed by most chromosomal and plasmid-mediated beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260766      PMCID: PMC172250          DOI: 10.1128/AAC.32.5.671

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

3.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

4.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  In vitro activities of Ro 19-5247 and Ro 15-8074, new oral cephalosporins.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

  7 in total
  16 in total

1.  In vitro activity of cefpodoxime against staphylococci in comparison to other cephalosporins.

Authors:  F Schumacher-Perdreau; B Jansen; G Peters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

Review 2.  Cefpodoxime proxetil in upper respiratory tract infections.

Authors:  E Bergogne-Berezin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Microbiological evaluation of cefpodoxime proxetil.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Cefpodoxime proxetil concentrations in head and neck tissues.

Authors:  H M Theopold; C Matthias; D Adam
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

6.  Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.

Authors:  H C Neu; G Saha; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.

Authors:  N Takasugi; N Tsunaga; N Sugino; F Numa; H Kato
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.

Authors:  D Höffler; P Koeppe; M Corcilius; A Przyklinik
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

10.  Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.

Authors:  H Knothe; P M Shah; O Eckardt
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.